Cardiovascular Events in Systemic Lupus Erythematosus: A Nationwide Study in Spain From the RELESSER Registry

This article estimates the frequency of cardiovascular (CV) events that occurred after diagnosis in a large Spanish cohort of patients with systemic lupus erythematosus (SLE) and investigates the main risk factors for atherosclerosis. RELESSER is a nationwide multicenter, hospital-based registry of SLE patients. This is a cross-sectional study. Demographic and clinical variables, the presence of traditional risk factors, and CV events were collected. A CV event was defined as a myocardial infarction, angina, stroke, and/or peripheral artery disease. Multiple logistic regression analysis was performed to investigate the possible risk factors for atherosclerosis. From 2011 to 2012, 3658 SLE patients were enrolled. Of these, 374 (10.9%) patients suffered at least a CV event. In 269 (7.4%) patients, the CV events occurred after SLE diagnosis (86.2% women, median [interquartile range] age 54.9 years [43.2–66.1], and SLE duration of 212.0 months [120.8–289.0]). Strokes (5.7%) were the most frequent CV event, followed by ischemic heart disease (3.8%) and peripheral artery disease (2.2%). Multivariate analysis identified age (odds ratio [95% confidence interval], 1.03 [1.02–1.04]), hypertension (1.71 [1.20–2.44]), smoking (1.48 [1.06–2.07]), diabetes (2.2 [1.32–3.74]), dyslipidemia (2.18 [1.54–3.09]), neurolupus (2.42 [1.56–3.75]), valvulopathy (2.44 [1.34–4.26]), serositis (1.54 [1.09–2.18]), antiphospholipid antibodies (1....
Source: Medicine - Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

Related Links:

The American Congress of Rehabilitation Medicine (ACRM) offers an opportunity for members to be the guest editor of a Supplement to its journal, the Archives of Physical Medicine and Rehabilitation (Archives). The goal of the ACRM supplements is to publish high quality scientific manuscripts, which are thematically organized and of interest to ACRM members and to the general readership of the Archives. We are interested in proposals in all fields of rehabilitation, but especially those of interest to the ACRM membership as indicated by the existence of special interest and networking groups for brain injury, spinal cord in...
Source: Archives of Physical Medicine and Rehabilitation - Category: Rehabilitation Tags: Organization news Source Type: research
Central fever following ischemic stroke is fairly common and associated with worse outcomes. Might the NSAID diclofenac sodium be an effective antipyretic in this situation?Journal of Medical Case Reports
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news
This study focused on the safety and efficacy of recanalizing therapies in heart failure patients with acute ischemic stroke. How does HF impact the long-term prognosis of these patients?Stroke
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news
A large meta-analysis finds that reducing sodium levels in our food lowers blood pressure in all of us, even those without hypertension, which could be a way to fight the number one killer: heart disease.
Source: CNN.com - Health - Category: Consumer Health News Source Type: news
Basel, 25 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for the fixed-dose combination (FDC) of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subc utaneous (SC) injection in combination with intravenous (IV) chemotherapy, for the treatment of eligible patients with HER2-positive breast cancer. The BLA for the FDC is based on results from the phase III FeDeriCa study, which demonstrated non-inferior levels of Perjeta in the blood (phar...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
ConclusionsOur results suggest that the peroxisome proliferator ‐activated receptor gamma 2Ala12 variant has significant protective effects against albuminuria and DN.
Source: Journal of Diabetes Investigation - Category: Endocrinology Authors: Tags: Original Article Source Type: research
AbstractBackground/ObjectiveNon ‐alcoholic fatty liver disease (NAFLD) is more and more common in patients with type 2diabetes mellitus (T2DM). Currently, some researches have found that Sodium glucose co‐ transporter2 (SGLT2) inhibitors, a new hypoglycemic drug, can improve nonalcoholic fatty liver besides hypoglycemic effect . Thus, we undertook a meta‐analysis of randomized controlled trials (RCTs) to evaluate the efficacy of SGLT2 inhibitors on the treatment of NAFLDMethodsPubMed, Embase and the Cochrane Library were searched for RCTs of SGLT2 inhibitors in patients with NAFLD and T2DM up to Oct1, 2019. Differenc...
Source: Journal of Diabetes Investigation - Category: Endocrinology Authors: Tags: ORIGINAL ARTICLE Source Type: research
ConclusionMetabolic biomarkers were affected by blood sample timing and underlying metabolic disease. The JECS will clarify the influences of metabolic status during pregnancy on the health and development of the offspring in future studies.
Source: Journal of Diabetes Investigation - Category: Endocrinology Authors: Tags: ORIGINAL ARTICLE Source Type: research
We present the case of a 12 ‐year‐old Japanese girl, who was positive for markers of both maturity‐onset diabetes of the young and latent autoimmune diabetes in youth. She was initially diagnosed with maturity‐onset diabetes of the young 1 based on the molecular analysis, and she later developed an autoimmune response , leading to β‐cell‐associated antibody‐positive diabetes. She was treated with incretin‐associated drugs and maintained adequate glycemic control. Pathophysiologically, there was an overlap between the two different types of diabetes, because the hyperglycemia and β‐cell stre...
Source: Journal of Diabetes Investigation - Category: Endocrinology Authors: Tags: Case Report Source Type: research
DiabetesMine answers key questions on the connection between type 1 diabetes and cardiovascular risk.
Source: Diabetes Mine - Category: Endocrinology Authors: Source Type: blogs
More News: Antiphospholipid Syndrome | Cardiology | Cardiovascular | Diabetes | Endocrinology | Heart | Heart Attack | Heart Disease | Hospitals | Hughes Syndrome | Hypertension | Internal Medicine | Ischemic Stroke | Lupus | Neurology | Peripheral Vascular Disease (PVD) | Smokers | Stroke | Study | Women